AAAAAA
Results:
1-7
|
Results: 7
Authors:
Van Pel, A
De Plaen, E
Duffour, MT
Warnier, G
Uyttenhove, C
Perricaudet, M
Boon, T
Citation: A. Van Pel et al., Induction of cytolytic T lymphocytes by immunization of mice with an adenovirus containing a mouse homolog of the human MAGE-A genes, CANCER IMMU, 49(11), 2001, pp. 593-602
Authors:
Grohmann, U
Fallarino, F
Bianchi, R
Belladonna, ML
Vacca, C
Orabona, C
Uyttenhove, C
Fioretti, MC
Puccetti, P
Citation: U. Grohmann et al., IL-6 inhibits the tolerogenic function of CD8 alpha(+) dendritic cells expressing indoleamine 2,3-dioxygenase, J IMMUNOL, 167(2), 2001, pp. 708-714
STAT5 activation is required for interleukin-9-dependent growth and transformation of lymphoid cells
Authors:
Demoulin, JB
Uyttenhove, C
Lejeune, D
Mui, A
Groner, B
Renauld, JC
Citation: Jb. Demoulin et al., STAT5 activation is required for interleukin-9-dependent growth and transformation of lymphoid cells, CANCER RES, 60(14), 2000, pp. 3971-3977
Authors:
Silla, S
Fallarino, F
Boon, T
Uyttenhove, C
Citation: S. Silla et al., Enhancement by IL-12 of the cytolytic T lymphocyte (CTL) response of mice immunized with tumor-specific peptides in an adjuvant containing QS21 and MPL, EUR CYTOKIN, 10(2), 1999, pp. 181-189
Authors:
Bilsborough, J
Van Pel, A
Uyttenhove, C
Boon, T
Van den Eynde, BJ
Citation: J. Bilsborough et al., Identification of a second major tumor-specific antigen recognized by CTLson mouse mastocytoma P815, J IMMUNOL, 162(6), 1999, pp. 3534-3540
Authors:
Fallarino, F
Uyttenhove, C
Boon, T
Gajewski, TF
Citation: F. Fallarino et al., Improved efficacy of dendritic cell vaccines and successful immunization with tumor antigen peptide-pulsed peripheral blood mononuclear cells by coadministration of recombinant murine interleukin-12, INT J CANC, 80(2), 1999, pp. 324-333
Authors:
Brandle, D
Bilsborough, J
Rulicke, T
Uyttenhove, C
Boon, T
Van den Eynde, BJ
Citation: D. Brandle et al., The shaved tumor-specific antigen encoded by mouse gene P1A is a target not only for cytolytic T lymphocytes but also for tumor rejection, EUR J IMMUN, 28(12), 1998, pp. 4010-4019
Risultati:
1-7
|